Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
Speaker: Yi (Benny) Yang, Ph.D. Chief Scientific Officer, Biocytogen Beijing
- Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets
- Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies
